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ABSTRACT: Development of drug delivery systems (DDS) is essential in many
cases to remedy the limitations of free drug molecules. Silica has been of great
interest as a DDS due to being more robust and versatile than other types of DDS
(e.g., liposomes). Using ibuprofen as a model drug, we investigated bioinspired silica
(BIS) as a new DDS and compared it to mesoporous silica (MS); the latter has
received much attention for drug delivery applications. BIS is synthesized under
benign conditions without the use of hazardous chemicals, which enables
controllable in situ loading of drugs by carefully designing the DDS formulation
conditions. Here, we systematically studied these conditions (e.g., chemistry,
concentration, and pH) to understand BIS as a DDS and further achieve high
loading and release of ibuprofen. Drug loading into BIS could be enhanced (up to
70%) by increasing the concentration of the bioinspired additive. Increasing the
silicate concentration increased the release to 50%. Finally, acidic synthesis conditions could raise loading eﬃciency to 62% while
also increasing the total mass of drug released. By identifying ideal formulation conditions for BIS, we produced a DDS that was
able to release ﬁvefold more drug per weight of silica when compared with MCM-41. Biocompatibility of BIS was also
investigated, and it was found that, although ∼20% of BIS was able to pass through the gut wall into the bloodstream, it was
nonhemolytic (∼2% hemolysis at 500 μg mL−1) when compared to MS (10% hemolysis at the same concentration). Overall, for
DDS, it is clear that BIS has several advantages over MS (ease of synthesis, controllability, and lack of hazardous chemicals) as
well as being less toxic, making BIS a real potentially viable green alternative to DDS.
KEYWORDS: nanomaterials, nanomedicines, pharmaceuticals, cytotoxicity, biomedical devices
1. INTRODUCTION
Drug molecules currently on the market, while eﬀective, can
have a whole range of limitations which reduce the eﬃcacy of
the drug. Some limitations include poor solubility, in vivo
degradation, and short systemic circulation times.1 Due to these
factors, to achieve eﬃcacy, drugs may require higher doses,
which can result in higher toxicity.1 One method of improving
drug eﬃcacy is by developing drug delivery systems (DDS).2
Aside from the obvious potential medicinal beneﬁts of DDS,
there are also large economic beneﬁts to be gained as new DDS
take signiﬁcantly less time and investment to develop than a
new drug molecule (3−4 years and approximately $20−50
million for DDS1 vs 10−12 years and $500 million for a new
drug3).
Many materials have been investigated for the use as DDS,
e.g., liposomes, polymeric nanoparticles (e.g., dendrimers), and
“hard” nanoparticles, mainly consisting of metals (e.g., gold),
metal oxides (e.g., iron oxide, titanium oxide, and silica) or
carbon.4−6 However, relatively few DDS are currently on the
market.7 The main limitations for any DDS becoming a clinical
product are the long regulatory journey coupled with issues
with biocompatibility, eﬃcacy, and the manufacturing pro-
cesses. Brieﬂy, a DDS must ﬁrst be proven to work and be safe
in vitro and then in vivo, manufacture should be straightfor-
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ward, and it should provide signiﬁcant beneﬁts over risks before
it can gain support from patents and ﬁnancial backing. Next,
human clinical trials are carried out and, if these are passed,
then the product will go on to become commercialized.7 This
long, multistep process can create obstacles for new DDS and
result in the failure of many of them. Due to the high failure
rate of DDS, there is huge potential for new developments in
this ﬁeld.
Here, we focus on silica as a DDS because there has been
increasing interest in the use of silica nanoparticles for the
purpose of drug delivery since 2001, when Vallet-Regi et al.
described the eﬀective loading and release of ibuprofen from a
type of mesoporous silica nanoparticle (MCM-41).8 The
successful use of a silica DDS over other systems (e.g.,
liposomes) has been attributed to its thermal and chemical
stability as well as versatility compared to those of conventional
drug delivery systems.9−12 Further, silica oﬀers a versatile
platform for functionalization with biomolecules to tailor drug
release as well as targeted delivery. One of the most common
methods of controlling drug release is through functionalizing
silica to create stimuli-responsive DDS. This opens up a wide
range of external stimuli which can be used to manipulate these
materials, ranging from magnetism, ultrasound, and light to the
more conventional temperature and pH.13−16 Functionalization
has also shown promise in targeted drug delivery. For example,
an interesting avenue is using silica functionalized with cell-
penetrating peptides for targeted delivery directly into
cytoplasm.17
Silica can be functionalized with various chemical groups,
making it compatible with a range of drugs. Examples of various
drugs investigated with silica range from anti-inﬂammatories
such as ibuprofen or aspirin, antibiotics such as gentamicin and
erythromycin, and antimalarials and anticancer drugs such as
doxorubicin and campothecin.8−10,18−27 While a gold-coated
silica product (Auroshell28) is in the ﬁrst stage of development
as an anticancer agent, there are currently no silica-based drug
delivery systems on the market, despite the fact that MS
showed some promise as an eﬀective DDS nearly 15 years ago.
This delay is due to several limitations, including long and
laborious synthesis (synthesis of MCM-41 can take between 10
and 146 h29−32) and use of harsh chemicals, toxic surfactants,
hazardous precursors, and harsh conditions (extreme temper-
atures and pH31). These imply that drug loading can occur only
postsynthesis, which adds another step (and extra time) to the
synthesis of this type of DDS. Therefore, a greener, economical,
scalable, and safer method of synthesizing silica with potential
for in situ drug loading is highly favorable.
Biomineralization of silica is observed in several species of
aquatic unicellular organisms such as diatoms (a class of
algae)33 as well as in more complex organisms such as some
sponge species and even in some plants.34−36 It was found that
speciﬁc proteins and biomolecules were involved in the
condensation of biosilica such as silicatein and silaﬃn.34−36
By understanding the chemistry and role of these biomolecules,
we developed analogues of these biomolecules (“additives”,
typically amines) which have been shown to rapidly condense
silica under benign conditions.37,38 As such, this has enabled
discovery of bioinspired silica (BIS) which can be controllably
synthesized at room temperature, at a neutral pH, in water, and
within 5 min.39 This also opens the possibility of in situ drug
loading, thus allowing a one step, green DDS formulation.40
Further, amine-ibuprofen interactions have been reported to be
favorable for drug delivery,41−43 which provides another
potential beneﬁt of BIS over MS: a possible additional function
of the amine additives.
As yet, only ﬁve papers have been published on the use of
BIS synthesis for drug delivery applications (including one from
our group40), suggesting a vast potential for future research. Li
et al. utilized a so-called “biomimetic” synthesis route; however,
this method retained all of the issues of synthesizing MCM-41
(i.e., long synthesis time, high temperatures, and requirement
for calcination).44 Begum et al. made use of surfactants to
create porosity; thus, their system still requires an energy
intensive calcination step as well as postsynthesis drug
loading.45 Sano et al. designed a drug molecule which had
the dual function of pharmacological activity and silica
condensation ability (not all drug molecules will have this
dual ability), meaning that the system was limited to only a
small set of drug molecules.46 Lechner et al. linked their cargo
molecule to a silica condensing peptide; however, they were not
able to fully control drug release. Conjugation of a peptide with
a drug has many other issues such as loss of drug activity, use of
hazardous chemicals, and also an extra synthesis step.47
Preliminary work from our group reported the green synthesis
of silica with in situ drug loading of calcein (a hydrophilic drug-
like molecule).40 This synthesis required no calcination, and the
amine additive was separate from the drug molecule. BIS did
not show any signiﬁcant toxic eﬀects to either ﬁbroblasts or
human monocytes in the resting state even at high silica
concentrations. However, mesoporous silica particles showed
substantially reduced cell viability even at low concentrations.
For example, the silica concentration required to reduce cell
viability to 50% (IC50) was 5−10 times more for BIS than for
MCM-41. Further, BIS did not induce secretion of inﬂamma-
tory cytokines at the concentrations proposed for use in DDS.40
From these results, it is evident that, despite the use of amine
additives, BIS is safe and does not cause concerning
cytotoxicity.
In the present study, we aimed to further extend BIS to a
pharmaceutically active drug molecule (ibuprofen) and create a
DDS formulation which, through carefully investigating and
understanding the formulation chemistry, would have the
ability to control the loading and release of pharmaceutically
active drugs. Ibuprofen was chosen because it is a commonly
used model drug for DDS development due to its small
molecular size (1.0 × 0.6 nm2),8 stability,48 ease of detection
(UV absorbance at ∼220 nm), and available literature on
ibuprofen-silica systems for comparison. The main aim of this
research is to primarily understand in situ drug loading into the
BIS system. Speciﬁcally, we plan to determine predictive rules
and investigate the eﬀects of the amine additive, drug
interactions, and silica chemistry on DDS performance (drug
loading and release proﬁles). Further, to make BIS a viable
DDS, it should exhibit loading and release proﬁles for ibuprofen
similar to or improved over those of the competitor MCM-41-
based DDS.
2. MATERIAL AND METHODS
2.1. Chemical Reagents. All reagents were purchased from Sigma
unless otherwise stated. Reagents included: acetronitrile (HPLC Plus,
≥ 99.9%), ammonia (NH3, anhydrous, ≥ 99.98%), anhydrous sodium
sulphite (97%), ammonium molybdate·4H2O, calcium chloride
hexahydrate (USP testing speciﬁcations), concentrated hydrochloric
acid, diethylenetriamine (DETA) (99%), dinitrophenol (≥98.0%)
(DNP), Dulbecco’s phosphate buﬀered saline (D-PBS), formic acid
(≥95%), glucose (≥99.5%), heparin, hexadecyltrimethylammonium
bromide (CTAB), hydrochloric acid solution 1 M (HCl, Fisher),
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ibuprofen (≥98%), Immu-mount, magnesium sulfate heptahydrate,
oxalic acid·2H2O (≥99.5%), pentaethylenehexamine (PEHA) (tech-
nical grade), potassium chloride (≥99.0%), PBS (tablets pH 7.4),
poly(allylamine hydrochloride) average Mw ∼17500 (PAH), poly-
(ﬂuorescein isothiocyanate allyamine hydrochloride) (poly(allylamine
hydrochloride):ﬂuorescein isothiocyanate 50:1), potassium phosphate
monobasic, sodium chloride (≥99.5%), sodium metasilicate pentahy-
drate (technical) (Fisher), sulfuric acid (98%), tetraehylenepentamine
(TEPA) (Acros Organics), tetraethoxysilane (TEOS) (99.999% trace
metal basis), and Triton X-100 (laboratory grade).
2.2. In Situ Drug Loading into BIS and Drug Release. To a
solution of sodium metasilicate in deionized water was added a
solution of amine additive (in water) followed by an ibuprofen
solution (in 70% ethanol). Then, a known volume of 1 M HCl (the
volume of HCl required varied depending on the amine additive used)
was added to reduce the pH of the solution to the desired pH (7,
unless otherwise stated). The concentrations of the reactants in the
ﬁnal solution were 30 mM sodium metasilicate, 1 mg mL−1 PAH, and
1 mg mL−1 ibuprofen: this ratio was termed 1:1:1. For a 50 mL batch
of 1:1:1, 0.3182 g of sodium silicate, 0.05 mL of PAH, and 0.05 g of
ibuprofen were used. When BIS was synthesized with other amines
(DETA, TEPA, and PEHA), a molar ratio of 1:1 [Si]:[N] was used.
This equates to 0.05155 g of DETA, 0.05678 g of TEPA, and 0.05809
g of PEHA for a 50 mL batch. Once acid was added, silica precipitated
within seconds, and the solution was left for 5 min before being
centrifuged at 8000 rpm for 15 min to stop the reaction. The
supernatant was stored at 4 °C to determine the drug loading
eﬃciency (percent of drug loaded into the silica) and drug content
(percent weight of drug in the silica-drug complex) via the method
described in Section 2.4. The silica pellet was resuspended, washed in
deionized water, centrifuged two more times (no detectable drug was
observed in these supernatants), and ﬁnally dried at 45 °C for at least 5
h.
Once dried, 10 mg of the silica was suspended in 1.4 mL of PBS
(pH 7.4) and incubated at 37 °C to measure drug release. At each time
point (1, 3, 5, 7, and 24 h time points), samples were centrifuged at
8000 rpm for 15 min, and 1 mL of the supernatant was used for high-
performance liquid chromatography (HPLC) analysis and replaced
with fresh PBS to satisfy the perfect sink conditions for determination
of the diﬀusion parameters. Release is expressed as the percent of the
loaded drug which has been released from 10 mg of silica. Each sample
was prepared in triplicate, and release proﬁles were measured from
each sample in triplicate.
2.3. Synthesis of MCM-41 and Postsynthesis Drug Loading.
MCM-41 was synthesized by ﬁrst dissolving CTAB in 300 mL of 25%
ammonia at 35 °C. While being stirred, 20 mL of TEOS was slowly
added. This solution was then stirred for 3 h and aged for 24 h at room
temperature in a closed container to allow silica to form. The product
was then vacuum ﬁltered and washed with 1 L of distilled water and
ﬁnally dried overnight at 85 °C. To remove the surfactant (CTAB),
MCM-41 was calcinated at 500 °C for 5 h. This was based on
previously published methods.12
To load the drug, 10 mg of MCM-41 was immersed in a 1 mg mL−1
solution of ibuprofen (in 70% ethanol) at 37 °C overnight. Samples
were centrifuged at 8000 rpm for 15 min, and the supernatant was
removed (and supernatant drug concentration was measured to
determine loading eﬃciency) and replaced with fresh PBS for a release
experiment. At each time point, samples were centrifuged at 8000 rpm
for 15 min, and 1 mL of the supernatant was taken for HPLC analysis
and replaced with fresh PBS.
2.4. Drug Detection via HPLC. Drug loading and release were
determined via an HPLC analysis method. A DIONEX system was
used with an autosampler (GINA50), pump (P580), and variable
wavelength detector (UVD170S) along with an ACE 5 C-18 column
(150 × 4.6 nm with 5 μm particle size) at room temperature. An
isocratic reverse phase HPLC method was used with a 30 μL injection
volume and a mobile phase of acetonitrile:0.1% formic acid (70:30) at
a ﬂow rate of 1 mL min−1. Ibuprofen retention time was approximately
4.7 min and was detected at a wavelength of 220 nm (λmax wavelength
of ibuprofen). Data were collected using Chromeleon V6.80 software,
and peaks were integrated to determine drug concentration. Data were
ﬁtted with a single exponential (eq 1) where Y0 is the ﬁnal release (%),
A is a constant, and R0 is the slope. When A and R0 were multiplied,
the maximum rate of release (% release per hour) was deduced.
= +y Y AeR X0 0 (1)
2.5. Material Characterization. Silica samples were characterized
using nitrogen adsorption in a micromeritics ASAP 2420 Accelerated
Surface Area and Porosimetry system. Samples were ﬁrst weighed and
degassed in optimum pressure and temperature conditions (120 °C).
They were then held at the boiling point of nitrogen and evacuated,
allowing nitrogen gas to enter the sample tubes while the pressure was
monitored. Analyses of the data included BET (Brunauer−Emmett−
Teller49) theory, used to characterize the surface areas of the silica
particles, and the BJH (Barrett−Joyner−Halenda50) theory, which
allowed for the characterization of the silica pore size distributions.
Silica samples were imaged by scanning electron microscopy (SEM)
using a Hitachi SU6600 ﬁeld electron SEM. Samples were mounted on
sample holders using sticky carbon tape and then gold splutter coated
under vacuum to prevent charging of the sample. Micrographs were
taken using a 20 kV potential diﬀerence and a working distance of 8.7
mm.
2.6. Measuring Movement of Silica across the Gut Wall. Rats
(200−250 g, male, Sprague−Dawley) were anesthetized via intra-
peritoneal injection with pentobarbitone (60 mg/kg) and sacriﬁced for
the experiment. The small intestine was removed and washed with 37
°C Krebs solution (made from distilled H2O, 16.09% (w/v) NaCl,
1.1% (w/v) KCl, 0.22 M KH2PO4, 2.74% (w/v) MgSO4·7H2O, and
0.12 M CaCl2·6H2O). Intestines were then inverted and bathed in
Krebs solution while ensuring the 37 °C temperature was kept
constant. Small sections of gut (∼5−6 cm) were cut and tied closed at
one end with thread and ﬁlled with 1 mL of fresh Krebs solution, and
then the open end was also tied closed.
To verify the health of the sections of gut, a control experiment was
set up which measured the passage of glucose across the gut wall.
Sections of gut were either immersed in 6 mL of a 1 mM glucose
solution or in a 1 mM DNP (dinitrophenol) solution (to inhibit the
active transport of glucose51) for 15 min at 37 °C before a glucose
solution (to make a ﬁnal concentration of 1 mM) was added. Sections
of gut were then incubated at 37 °C for an hour before being cut open
and their contents removed. Glucose concentrations were measured
using a glucose (gluc-pap) assay kit purchased from Randox.
To measure the passage of silica through the gut wall, ﬂuorescent
silica was prepared using the same method as in Section 2.2 except that
PAH-FITC was used as the amine additive, thus creating ﬂuorescently
labeled silica. Fluorescence was measured on a RF-530IPC ﬂuorometer
at an excitation wavelength of 495 nm and an emission wavelength of
515 nm. Tubes of inverted rat gut sections were incubated in a 1 mg/
mL silica solution (in Krebs) or a 1 mg mL−1 silica solution and 1 mM
DNP for an hour at 37 °C. Gut sections were then cut open, their
contents removed, and their ﬂuorescence measured; the sections were
then ﬁxed in a formalin solution (neutral buﬀered 10%) for 30 min
followed by two PBS (pH 7.4) washes. The inside and outside surfaces
of the gut sections were then imaged using a Carl Zeiss Axio Imager
Z1 with 10×/0.30 lens. Sections of gut were mounted either by
stretching the gut and pinning the edges or compressing gut sections
under Immu-mount and coverslips.
2.7. Hemolytic Activity of Silica. To measure the hemolytic
activity of silica, rats (Sprague−Dawley) were bled, and the blood was
stabilized with heparin (100 μL of 1000 units ml−1). Four milliliters of
heparin stabilized blood was diluted with 9 mL of Dulbecco’s PBS and
centrifuged at 2250g for 5 min. The supernatant was carefully
removed, and the blood was washed ﬁve times with D-PBS. After the
last wash, the red blood cells (RBC) were diluted with 40 mL of D-
PBS. Diluted RBC (0.2 mL) were then added to 0.8 mL of silica
suspension at the desired concentration to make a ﬁnal silica
suspension. Positive and negative controls were set up by adding 0.2
mL of RBC to either 0.8 mL D-PBS or 0.8 mL of 0.2% Triton X-100.
All samples were prepared in triplicate and brieﬂy vortexed before
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being left static at room temperature for 4 h. Samples were then
vortexed again and centrifuged at 10000g for 2 min. Supernatant (10
μL) was used to test the absorbance of hemoglobin using an
anthos2020 plate reader at 577 nm with a reference wavelength of 655
nm. Hemolysis was calculated as % hemolysis = [(sample absorbance
− negative control)/(positive control − negative control)] × 100.52
3. RESULTS AND DISCUSSION
In order for BIS to be developed as an eﬀective DDS, one must
understand the synthesis chemistry and the mechanisms that
dictate the loading and release of drug molecules from the
system. There has been little information published on the
loading mechanics of the BIS system and it has been
speculated, but not proven, that embedded amine, originally
employed to facilitate silica condensation, also helps to
functionalize the silica.40 If this is the case, then the BIS DDS
can be synthesized, functionalized, and drug-loaded all in one
step, which is a vast improvement on the long multistep process
involved in MS. All of these possibilities were investigated
herein.
3.1. Eﬀect of the Amine Additive on the Loading and
Release of Ibuprofen. The eﬀect of the choice of amine
additive for the synthesis of BIS upon its ability to load and
release calcein (a nonpharmaceutically active but “drug-like”
molecule) has previously been reported.40 As these eﬀects are
drug speciﬁc, we investigated them for an active drug molecule
(ibuprofen) in the BIS system and compared earlier results for
calcein with those for ibuprofen.
To screen the most suitable systems, four additives were
investigated: three small amines and one polyamine. These
were chosen based on their silica precipitation performance and
previous investigations into BIS.37,38,40,53 We measured the
loading eﬃciency (amount of drug loaded on DDS when
compared to the concentration used for loading), drug content
in the DDS (amount of drug loaded per weight of DDS), and
total amount of drug released (mg drug/10 mg DDS). DETA, a
small amine, was immediately excluded for use as it had a
Figure 1. BIS synthesized with diﬀerent amines. (A) Percent loading eﬃciency and percent drug content (w/w) of ibuprofen loaded into four
diﬀerent BIS and MCM-41 systems. (B) Percent release of loaded ibuprofen from four diﬀerent BIS and MCM-1 systems. (C) Total mass of
ibuprofen (mg) released from 10 mg of silica sample. (D) Surface area, pore volume, and pore size ﬁgures for four diﬀerent BIS and MCM-41
systems (an asterisk represents that speciﬁc pore sizes are not applicable due to broad pore size distributions). For A, B, and C, n = 3; error bars
represent one standard deviation. For D, n = 1.
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loading eﬃciency of only <5% (Figure 1A). The other amines
used were PEHA, TEPA, and PAH, and they exhibited loading
eﬃciencies of 20−30%, while MCM-41 showed ∼40% loading
eﬃciency (Figure 1A). These diﬀerences between BIS and
MCM-41 are likely due to the diﬀerent methods by which the
drug was loaded into these two types of silica. For BIS,
ibuprofen was loaded in situ, and the drug would have been
entrapped within the silica particles followed by some surface
physisorption. With MCM-41, only postsynthesis loading was
possible, and drug loading was entirely reliant on physisorption
(hence surface area and porosity is important in this system).
Focusing on drug release from these DDS, despite having
loading eﬃciencies similar to those of BIS-PAH, BIS-TEPA and
BIS-PEHA released <2% of the loaded drug, and as such, these
amines must also be discarded (Figures 1B and C).
Approximately 22% of loaded ibuprofen was released from
BIS-PAH compared to the 39% released from MCM-41
(Figure 1B and Table S1). The release data appeared to ﬁt
well using a single exponential equation with >0.9 R2 values in
all cases (Table S1). The ﬁtting showed that BIS-DETA, BIS-
TEPA, and BIS-PEHA all had very low release rates (Figures
1B and C). However, the rates of release (Table S1) from
MCM-41 and BIS-PAH were similar (15 and 17% per hour,
respectively).
The drug loading eﬃciency on MCM-41 was found to be
41%, while the loading eﬃciency for BIS-PAH was 23% (Figure
1A). Despite this, MCM-41 released around half the amount of
drug when compared to BIS-PAH (0.12 mg compared to 0.28
mg for 10 mg DDS, respectively). This implies that for a dose
of 1 mg of ibuprofen, a patient would have to take ∼83 mg of
MCM-41 compared to only ∼54 mg of BIS-PAH. High doses
of MCM-41 silica can result in serious toxicity issues, unlike
with BIS,40,52 which highlights a key beneﬁt of using BIS.
The diﬀerences in release proﬁles between BIS synthesized
with the diﬀerent amines are likely to be due to the porosity
and morphology characteristics of the synthesized silica
(Figures 1D and S1B). Adsorption of drugs is a function of
pore size, pore volume, and surface area; particle size does not
have any impact on release.54,55 In the case of MCM-41 (a
mesoporous silica), it is generally accepted that porosity is a
major factor in controlling the release of drugs, and so further
investigation was needed to determine whether this was the
case for BIS.43,56,57 BIS-DETA, TEPA, and PEHA all have a
very small pore volumes (∼0.1 cm3/g) and low surface areas
(∼20−40 m2/g) (Figure 1D). The pore volume and surface
area for BIS-PAH (0.74 cm3/g and 129 m2/g, respectively)
were higher than those of silica synthesized with the other three
amines. This suggests that silica particles synthesized with any
of the small amines were dense when compared to BIS-PAH,
which explains the higher release from BIS-PAH within the BIS
series. These observations explain why the BIS-DETA, TEPA,
and PEHA samples exhibit poor drug loading/release when
compared with BIS-PAH. Interestingly, MCM-41 has a much
larger surface area (989 m2/g) than any of the BIS samples but
Figure 2. Eﬀect of reactant concentrations on the loading and release proﬁles of ibuprofen. (A) Percent loading eﬃciency and percent drug content
(w/w) of ibuprofen loaded into BIS synthesized with diﬀerent reactant ratios and MCM-41. (B) Percent release of loaded ibuprofen from four
diﬀerent BIS and MCM-41 systems. (C) Total mass of ibuprofen (mg) released from 10 mg of silica sample. (D) Surface area, pore volume, and
pore size ﬁgures for BIS synthesized with diﬀerent reactant concentrations and MCM-41. For A−C, n = 3; error bars represent one standard
deviation. For D, n = 1.
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demonstrated loading eﬃciency comparable to that of BIS-
PAH. SEM revealed that BIS-PAH particles were fairly uniform
in shape and size, exhibiting a range between 72 ± 17 and 78 ±
18 nm (Figures S2A and B) without and with the drug,
respectively, thus suggesting that the presence of the drug did
not aﬀect the particle sizes signiﬁcantly. On the other hand,
MCM-41 samples used herein were not only very large in
comparison (3340 ± 1013 nm, Figures S1A and B) but also
nonuniform with large variations in size and shape. Further, it is
interesting to note that, despite the diﬀerence in particle size
between MCM-41 and BIS-PAH, the amounts of drug released
were often comparable. At this point in time, a direct
comparison between these two DDS is not possible simply
based on SEM results because of their distinctly diﬀerent drug
loading mechanisms, and further analysis in future is necessary.
Along with porosity altering the release of ibuprofen, it has
been reported that the amine-ibuprofen interaction is important
in loading.40,42,58 Because BIS-TEPA and BIS-PEHA showed
over 30% drug loading eﬃciency, it is possible that the amine
additives facilitate ibuprofen loading through favorable amine-
drug interactions as reported elsewhere41−43,58 but that they
also form nonporous silica by fully encapsulating ibuprofen
within the dense silica particles, thus resulting in very low
release. PAH, however, allows ibuprofen loading through
favorable interactions with amine groups, and release occurs
through the silica pores. These observations are consistent with
the literature, where it has been reported that these small
amines lead to the formation of dense and nonporous silica,
while PAH forms porous silica.37,38
Figure 3. Eﬀect of reaction pH on the loading and release proﬁles of ibuprofen. (A) Percent loading eﬃciency and percent drug content (w/w) of
ibuprofen loaded into BIS synthesized at diﬀerent pH and MCM-41. (B) Percent release of loaded ibuprofen from silica. (C) Release of loaded
ibuprofen expressed as a percent of ﬁnal concentration released from BIS synthesized at a range of pH values. (D) Total mass of ibuprofen (mg)
released from 10 mg of silica sample. (E) Surface area, pore volume, and pore size ﬁgures for BIS synthesized at diﬀerent pH value and MCM-41
samples. For A, B, and D, n = 3; error bars represent one standard deviation. For C and E, n = 1.
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3.2. Altering Reactant Concentrations To Understand
the Silica-Drug System. The main aim here is to understand
the DDS and investigate how controllable it is with ibuprofen
so that this knowledge can be implemented for other drugs. As
such, our next step was to study the eﬀects of reaction
chemistry on DDS performance. There has been some evidence
that altering reactant concentrations can alter the loading and
release proﬁles of calcein from BIS synthesized with PAH;40
however, the reasons behind this eﬀect were not fully
investigated. Therefore, a systematic approach by varying
synthesis conditions and evaluating their eﬀects on drug loading
and release has been taken while keeping the starting
concentration of ibuprofen in the reaction mixture constant
(1 mg mL−1).
Figures 2A and Table S2 show that for MCM-41 (as
reported in the section above), the loading eﬃciency was ∼40%
and the drug content was ∼3 wt %. The loading eﬃciency and
drug content for the 1:1 BIS-PAH sample (30 mM solution of
sodium metasilicate and a 1 mg mL−1 solution of PAH) were
∼22% and 13 wt %, respectively. When the concentrations of
silicate and PAH were doubled (2:2), there was a doubling of
ibuprofen loading eﬃciency (Figure 2A). This was attributed
simply to more silica being formed (Table S2) because the drug
content did not change (Figure 2A). When only the silicate
concentration was increased and the PAH concentration was
kept at 1 mg mL−1 (2:1), there was a slight increase in
ibuprofen loading eﬃciency (Figure 2A), but drug content
remained unchanged, which was attributed simply due to an
increased silica yield (Table S2). Producing more silica means
that more ibuprofen was loaded (and so less was wasted by
being left in the reaction mixture). Interestingly, when a
synthesis ratio of 1:2 (increasing PAH concentration but
maintaining silicate concentration) was investigated, drug
loading eﬃciency increased 3-fold to 75% (Figure 2A). This
loading eﬃciency (which was signiﬁcantly higher than that
found for MCM-41 (∼40%)) was produced from a signiﬁcantly
lower silica yield (Table S2). The drug content also increased
substantially from ∼10% for 1:1 to ∼70% for 1:2. This is likely
due to a drug-amine interaction, suggesting that the amine can
have a dual function of facilitating silica condensation as well as
acting as a functionalization agent to facilitate drug loading (see
Section 3.3 for further discussion). These loading studies
highlight that the synthetic conditions can readily modulate the
loading eﬃciency of BIS and even reach loadings that are
signiﬁcantly higher than what is achievable with MCM-1.
Finally, the release of ibuprofen from these samples was
investigated, and it was found that the overall release of
ibuprofen from diﬀerent silica varied. BIS-PAH (1:1) released
22% of the loaded ibuprofen, and 2:2 and 2:1 both achieved
higher releases (45 and 50%, respectively), which were greater
than the 39% released from MCM-41 (Figures 2B and C). It is
possible that release from 2:2 and 2:1 was higher than that from
1:1 due to faster silica condensation because the silica precursor
concentration used was doubled.59 This resulted in lower pore
volumes and smaller pores (Figures 2D and S3B), leading to
less drug being entrapped within the silica and remaining
mainly as surface bound, making release easier. In contrast, a
1:2 ratio released only 6% of loaded ibuprofen (Figure 2B)
despite a very high loading eﬃciency and larger pore size
(Figures 2D and S3B).
When the release proﬁles were considered (Figure S3A), all
but the 2:1 samples exhibited burst release, where the majority
of drug was released over the ﬁrst 5 h and very little release was
observed after this point (Table S2). This suggests that the
ibuprofen that is able to escape is mainly surface bound and any
ibuprofen embedded within the silica particles is trapped and
unable to be released. This idea is supported by Figure S3A
where all the BIS release proﬁles were similar to the release
proﬁle of MCM-41, which only had surface bound ibuprofen
loaded. However, the 1:2 system had a much lower maximum
release rate than the other systems (Table S2) as well as low
total release (Figure 2B). Table S2 also shows that the mass of
ibuprofen released from all the BIS systems were higher than
from MCM-41, some BIS samples releasing 5x more drug per
weight of silica than MCM-41. This is important since if more
mg of drug is released then less silica will need to be
administered to a patient.
3.3. Understanding Additive-Drug Interactions To
Control DDS Formulation. Ibuprofen contains a carboxylic
acid group, which is expected to interact with amines. Several
studies have exploited these favorable amine-ibuprofen
interactions by postsynthetically functionalizing MS.41−43,58 In
addition, from the results presented above, there was an
indication that the PAH-ibuprofen interactions are important
for drug loading and release. Therefore, we investigated
whether drug loading and release could be controlled by
tuning PAH-ibuprofen interactions by varying the synthesis pH
(and in turn the protonation). In this study, silica was usually
formed at pH 7 as silica formation is the quickest at neutral pH
for this synthesis method.40,59 BIS will not readily form outside
the pH ranges of 5−9; hence, we focused on exploring drug
loading under this pH range and monitored the eﬀect of
formulation pH on the drug release (Figure 3).
When silica was condensed at pH ≥ 7, the loading eﬃciency
was not altered (remaining at ∼20%, Figure 3A). When the
synthesis pH was more acidic, on the other hand, ibuprofen
loading eﬃciency could be enhanced up to three times (to
60%) at pH 5. A similar picture was observed for the drug
content (wt %) shown in Figure 3A. The release for samples
formulated at pH ≤ 7 was similar (Figure 3C and Table S3),
whereas DDS formulated at pH ≥ 7 had greatly diminished
release. It should be noted that all release experiments were
carried out in PBS at pH 7.2. Interestingly, despite the higher
drug loading at pH 5, there was no corresponding higher
release observed when compared with DDS formulated at pH 7
(Figure 3B). Despite this, the total ibuprofen (mg) released per
weight of silica for the pH 5 sample was 10 times higher than
that for the MCM-41 sample (Figure 3D)
When release was plotted as a fraction of total release over
time, two diﬀerent release proﬁles became apparent (Figure
3C). BIS-PAH synthesized at pH ≤ 7 exhibited a burst release
proﬁle similar to those observed for BIS samples reported
above (also evident from high release rates, Table S3), where
the majority of ibuprofen was released from the silica in the ﬁrst
5 h, and very little was released after this. This burst release
proﬁle was similar to that seen for MCM-41, suggesting that the
main mechanism for release in these systems was release from
the surface. However, silica synthesized at pH > 7 appeared to
have a slow and sustained release proﬁle, which was also
reﬂected in slow release rates (Table S3). Release did not
plateau for 24 h, and ibuprofen maintained a slow release over
the course of the experiment. This slow release suggested that
the loaded ibuprofen was embedded within the silica rather
than bound to the surface, making release more prolonged.
While the total amount of ibuprofen released from these
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samples under the 24 h observation window was low, this
system does show some promise as a prolonged release system.
It is clear from the results presented that the DDS
formulation pH controlled the loading and release of ibuprofen.
This could be caused by diﬀerences in porosity, morphology,
and/or additive-drug interaction. SEM results suggested that
pH did not have a signiﬁcant eﬀect on the morphology or
particle sizes of DDS (Figures S2A and B). When surface area
and pore volume were measured for BIS-PAH DDS formulated
at diﬀerent pH conditions, there were no signiﬁcant diﬀerences
observed (Figures 3E and S4). The diﬀerences in ibuprofen
loading in these systems can then likely be attributed to
ionization of the three components present (silica, amine
additive, and drug) in the reaction mixture as well as the silica
formation pathways. A scheme showing how the proportions of
ionized reactants vary as the reactant pH is altered can be seen
in Figure 4 and Table S4. The results here suggest that the
negative charge on silica can have an inhibitory eﬀect on
loading eﬃciency. Both the silica surface and ibuprofen are
negatively charged at pH ≥ 7 (Table S4), and therefore silica
and the drug will repel one another, thus explaining low loading
eﬃciencies at pH ≥ 7 (only ∼20% of ibuprofen was loaded
under these conditions, Figure 3A and Table S3). With DDS
formulations prepared under acidic conditions, and particularly
at pH 5, the silica and ibuprofen are both signiﬁcantly less
charged, thus allowing ibuprofen to be more eﬃciently loaded
(30−60% of ibuprofen was loaded under acidic conditions,
Figure 3A and Table S3).
It is clear that pH has a drastic eﬀect on the loading eﬃciency
of ibuprofen into BIS, with more acidic conditions resulting in
increased loading. There is also strong evidence of an amine-
drug interaction playing a major role in the ability of BIS to
load the drug. This interaction, when too strong, can also
inhibit drug release.
3.4. Biocompatibility of BIS. Due to the ease and
noninvasive nature of administration, oral delivery of drugs is
the most preferred route for patients.60 Silica is an ideal
material for oral drug delivery due to its stability under the
conditions found in the gastrointestinal tract, especially the low
pH found in the stomach (pH 1−3), and therefore it is able to
protect the loaded drug molecules from the changes in pH as
well as degradative enzymes and bile salts.61,62 While amine
functionalization is beneﬁcial for drug loading and controlling
release, exposure of amine-functionalized MS to cells has been
reported to result in a higher cytotoxicity,40 higher level of
plasma membrane damage, and higher hemolytic activity.52 BIS
was reported to be either noncytotoxic, toxic only at extremely
high concentrations, or when internalized into activated
macrophages.40 To further improve our understanding of BIS,
it is important to uncover the fate of orally administered silica.
A simple and eﬀective experiment was set up using sections
of rat gut and measuring the movement of ﬂuorescently tagged
BIS-PAH (FITC-BIS-PAH) across the gut wall over an hour.
FITC-BIS-PAH was synthesized using FITC-tagged PAH so
that its movement through the gut wall could be measured. We
observed that ∼22% of silica moved across the gut wall during
the hour-long incubation (Figure 5). This movement was
through passive diﬀusion because it was not aﬀected by the
addition of an inhibitor of active transport (DNP). To further
observe the movement of silica particles through the gut wall,
ﬂuorescence microscopy images of the inner and outer surfaces
of the rat gut were taken (Figure 5). It is clear that when no
silica is present, there are no deﬁned points of ﬂuorescence, but
in the gut sections exposed to silica and silica with DNP,
deﬁned points of silica are observed. Silica was clearly localized
on both sides of the gut wall, conﬁrming its movement. Due to
Figure 4. Scheme to illustrate the diﬀerences in charge of silica, amine,
and ibuprofen during synthesis at pH values ranging from 9 to 5.
Figure 5. Light and FITC microscopy images of the inside and outside
surfaces of rat gut incubated with no silica (control), ﬂuorescent silica,
or ﬂuorescent silica and DNP. Images were taken using a Carl Zeiss
Axio Imager Z1 with a 10×/0.30 lens.
ACS Biomaterials Science & Engineering Article
DOI: 10.1021/acsbiomaterials.6b00224
ACS Biomater. Sci. Eng. 2016, 2, 1493−1503
1500
the ability of BIS-PAH to pass through the gut wall, it became
important to investigate its biocompatibility with other cell
types, particularly RBC.
The eﬀect of BIS on RBC was determined through hemolytic
activity of BIS when exposed to RBC. Figure 6 shows that BIS-
PAH had very low hemolytic activity, lysing only 2% of RBC at
the highest concentration used (500 μg/mL) and only 0.6% at
the concentration which passed through the gut wall (∼250
μg/mL). MCM-41 exhibited a higher hemolytic activity, rising
to 10% at 500 μg/mL. The reasons behind this diﬀerence were
initially unclear but may be related to the size of the particles. It
has been reported that silica particle size aﬀects hemolysis.63
BIS-PAH particles were spherical (78 ± 18 nm in diameter,
Figures S2A and B) and signiﬁcantly smaller than the irregular
MCM-41 particles used (3340 ± 1013 nm in diameter), which
could partly explain the diﬀerence in hemolytic activity between
BIS and MCM-41. SEM data also show that, although BIS
primary particles were <100 nm, they form micrometer-sized
agglomerates and rapidly precipitate (hence DLS was not
possible or useful). It is thus expected that BIS particles are as
toxic as MCM-41 simply based on their sizes, but this was not
observed. Although further work is required on BIS to fully
understand their biocompatibility, our present and previous
results show that BIS is more biocompatible than MS.
4. CONCLUSIONS
Our primary aim was to develop an in situ drug loading and
release system using BIS. The BIS system can be controlled
using many factors such as the choice of amine additive, pH of
synthesis, kinetics of synthesis, and eventual location of the
drug within the silica (Figure 7). Our results identiﬁed that the
ideal formulation is BIS-PAH synthesized with a reactant ratio
of 2:2. Formulation under an acidic pH was found to be
suitable for designing DDS for faster targeted release, while
basic pH was preferred for sustained release (Figure 7).
Although a small portion of BIS-PAH was able to pass through
the gut wall into the bloodstream, due to its low hemolytic
activity, that does not appear to be an issue, in contrast to
MCM-41. Ultimately, BIS appears to have several advantages
over MCM-41 (such as one step formulation, simple
controllability, and lack of hazardous chemicals), and it was
found that BIS has drug loading and release proﬁles similar to
or improved over those of MCM-41 in addition to superior
biocompatibility. These beneﬁts give BIS real potential as a
viable DDS to be further investigated. We believe that the
understanding of the DDS formulation using BIS that has
emerged from this work can enable the discovery and
development of a wide variety of DDS.
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